Chinese Clinical Oncology

Effects of Nrf2 gene silencing by RNA interference on biological behaviors of esophageal carcinoma cells

ZHANG Jun， KONG Deyou， ZHANG Jian， KONG Jie， ZHANG Andu.

Chinese Clinical Oncology. 2014, 19 (12): 1057.

Abstract ( 1041 )

PDF（pc） (1634KB) ( 505 )

Save

Objective To investigate the effect of down-regulation of nuclear factor erythroid 2-related factor（Nrf2） by RNAi on biological behaviors in esophageal cancer cells. Methods Eca-109 cell line which was down-regulated Nrf2 by RNAi（Si-Nrf2） and negative control cell（Si-control） were established. Si-Nrf2 cells and Si-control cells were transfected by Lipofectamine 2000. Cell proliferation， apoptosis， cell metastasis and relative protein expression were analyzed by MTT assay， colony formation assay， flow cytometry， transwell and western blotting method after transfection. Results Western blotting showed that the expression of Nrf2 in the Si-Nrf2 cells was 0.209±0.013， which was significantly lower than that in the Sicontrol cells（0.852±0.077， P＜0.05）. The result of biological function shown that Eca-109 cell down-regulated Nrf2 had a lower survival fraction， higher cell apoptosis， and significant decrease in migration and invasion， higher radiosensitivity and lower expression of HO-1， Bcl-2， MMP-9 protein compared with those of Si-control cells（P＜0.05）. Conclusion Nrf2 may involve biological process of cell proliferation， apoptosis， invasion and metastasis and radiation sensitivity in esophageal cancer by regulating the expression of HO-1， Bcl-2 and MMP-9 protein.

Related Articles | Metrics

Influences of recombinant human endostatin on angiogenesis

YE Qing， QIN Shukui， YIN Xiaojin， LIU Yanhong， FENG Jundong， WU Qiong， QU Wenshu.

Chinese Clinical Oncology. 2014, 19 (12): 1062.

Abstract ( 1028 )

PDF（pc） (3253KB) ( 360 )

Save

Objective To study the effects of recombinant human endostatin（endostar） on the angiogenesisrelated biological behaviors such as chemotaxis， migration， adhesion， proliferation and tube formation of vascular endothelial cells.Methods With primary cultured human umbilical vein endothelial cells（HUVEC） as a model， the fluorescence quantitative Boyden chamber analysis， wound healing assay， fluorescence quantitative adhesion assay， flow cytometry， tube formation assay and Matrigel plug test were employed to evaluate the effects of endostar on the angiogenesisrelated biological behavior of HUVECs in vitro and in vivo. Results Endostar potently inhibited HUVEC migration in response of VEGF from 50 to 50000ng／ml， and its significant concentrations were 50ng／ml and 500ng／ml. Endostar inhibited HUVEC migration towards damage between 50ng／ml and 50000ng／ml in a dosedependent manner. Compared with 0ng／ml， the endostar at the dose of 50， 500 and 5000ng／ml decreased adhesion rate and proliferation rate of HUVEC cells as well as the number， area and length of HUVEC mesh tubular with statistically significant difference（P＜0.05）. Matrigel plug test also revealed that Endostar inhibited Matrigel plug formation in SCID mice between 50ng／ml and 50000ng／ml. Conclusion At the cellular level， endostar inhibited the angiogenesisrelated biological behaviors of HUVECs， including migration， adhesion， proliferation and tube formation. In vivo， endostar inhibited the angiogenesis in SCID mice.

Related Articles | Metrics

Effects of Carfilzomib combined with CPT-11 on the proliferation， apoptosis and NF-kappa B（NF-κB） of gastric cancer SGC-7901 cells

ZHOU Lianghua， WANG Mingyuan， WANG Xing.

Chinese Clinical Oncology. 2014, 19 (12): 1069.

Abstract ( 987 )

PDF（pc） (1797KB) ( 372 )

Save

Objective To explore the effects of Carfilzomib （CFZ） combined with irinotecan （CPT-11） on the proliferation， apoptosis and NF-kappa B of gastric cancer SGC-7901 cells. Methods The proliferation inhibition rates after treatment with different concentrations of CFZ （0， 0.1， 1， 10， 50，100nmol／L）， CPT-11 （0， 2.5， 5， 10， 50， 100μmol／L） or 100nmol／L CFZ plus 100μmol／L CPT-11 were analyzed via MTT colorimetric assay at 24， 48， 72 and 96h. The flow cytometry with Annexin V／PI double staining was used to evaluate the combined effect of CPT-11 and CFZ on apoptosis and cell cycle at 48h， respectively. The intracellular activation of caspase-3 was detected by flow cytometry. Western blotting method was used to measure the protein levels of NF-κB and IκB-α as well as the activation status of PI3K／Akt signaling pathway. Results The co-administration of CFZ and CPT-11 or single-agent treatment could increase the proliferation inhibition rates of SGC7901 cell in a time- and dose-dependent manner， while there were higher proliferation inhibition rate in co-administration versus singleagent treatment （P＜0.05）. Compared with the single-agent treatment， the co-administration of CFZ and CPT-11 presented increasing apoptosis rate， activation rate of caspase-3， proportion of S phase and IκB-α level but decreasing proportion of G2／M cell phase， NF-κB p65 and p-Akt level （P＜0.05）. Conclusion Both CFZ and CPT-11 exhibited cytotoxicity on SGC-7901 cell， including proliferative inhibition， induction of apoptosis， downregulation of NF-kappa B and suppression of the activation of PI3K／Akt signaling pathway. CFZ combined with CPT-11 have a synergistic effect on gastric cancer cells.

Related Articles | Metrics

Expression and clinical value analysis of plasma miR-223， miR-93 and miR-218 in non-small lung cancer

CAI Jingqing， WANG Ning， ZHANG Min.

Chinese Clinical Oncology. 2014, 19 (12): 1075.

Abstract ( 1011 )

PDF（pc） (952KB) ( 365 )

Save

Objective To explore the levels of plasma miR-223， miR-93 and miR-218 in non-small lung cancer（NSCLC） and analysis the relationship between the 3 indicators and clinicopathological parameters of NSCLC.
Methods Plasma samples from 85 NSCLC patients before treatment were collected as NSCLC group. The real-time quantitative RT-PCR（qRT-PCR） was used to detect the levels of miR-223， miR-93 and miR-218 and the clinicopathological parameters of NSCLC patients were collected. The clinicopathological parameters of patients with different levels of miR-223， miR-93 and miR-218 were compared. The receiver operating characteristic curve（ROC） was employed to analysis the clinical value of plasma miR-223， miR-93 and miR-218 in the diagnosis of NSCLC. Meanwhile， the plasma samples from 90 healthy volunteers at the same time were selected as control（control group）. Results There were higher levels of miR-223 and miR-93 but lower miR-218 in NSCLC group compaired with control group with significant difference（P＜0.05）. The level of miR-223 was related with TNM stage and tumor size， and miR-93 was related with histological type and lymph node metastasis， and miR-218 was related with tumor size and degree of differentiation, showing with significant difference（P all＜0.05）. The plasma level of miR-223 was positively correlated with miR-93（r=0.411）， but miR-223 and miR-93 were negatively correlated with miR-218（r=-0.361 and r=-0.451）with statistically significance（P＜0.05）. The AUC， sensitivity and specificity of plasma miR-223， miR-93 and miR218 in the diagnosis of NSCLC were 0.926， 95.2％ and 87.1％， 0.912， 88.4％ and 92.5％， and 0.941， 92.7％ and 84.4％， higher than 0.774， 75.1％ and 66.2％ of carcinoembryonic antigen（CEA）. The combined efficiency of miR-223， miR-93 and miR-218 in NSCLC was superior to that alone. Conclusion There are higher expression of miR-223 and miR-93 but lower expression of miR-218 in NSCLC. The plasma levels of the above indicators are related with clinical pathology parameters， showing a certain value in the diagnosis of NSCLC as assisted indicators in the diagnosis of NSCLC.

Related Articles | Metrics

Expression of CCR4 in T1 stage lung adenocarcinoma and its clinical significance

QIANG Guangliang， LIU Deruo， NAKAJIMA Jun， ANRAKU Masaki， NITADORI Junichi，USHIKU Aya.

Chinese Clinical Oncology. 2014, 19 (12): 1081.

Abstract ( 981 )

PDF（pc） (2216KB) ( 394 )

Save

Objective To investigate the expression of CC chemokine receptor 4（CCR4） in tumor infiltrating lymphocytes（TILs） of T1 stage lung adenocarcinoma and analyze its correlation with clinicopathological characteristics and prognostic impact. Methods The expression of CCR4 in TILs was quantified by tissue microarray and immunohistochemistry in 185 T1 stage adenocarcinomas. The relationship between the expression of CCR4 in TILs with clinicopathological characteristics and prognosis was analyzed. Results The expression of CCR4 was located in the nucleus of lymphocytes， with a positive expression ratio of（17.8±7.3）％. And patients were devided into high expression group and low expression group according 17.8%. The CCR4 expression was correlated with T stage， nodal involvement， lymphovascular invasion， and relapse（P＜0.05）， but not with age， gender or smoking history（P＞0.05）. The 5year overall survival rate of CCR4 was 88.1％， lower than that of CCR4 low expression group（89.8％） with statistically significant difference（P=0038）. The 3-year overall survival rates of CCR4 high expression group and low expression group were 98.7％ and 88.1％， the 5-year overall survival rates were 89.8％ and 88.1％，and the 8year overall survival rates were 86.6％ and 51.6％，with statistical significance（P＜0.05）；The 3-year recurrence-free survival rates of CCR4 high expression group and low expression group were 93.3％ and 82.3％， 3-year recurrencefree survival rates were 86.4％ and 74.5％， and 8-year recurrencefree survival rates were 83.4％ and 50.5％ with statistical significance（P＜0.05）. Conclusion The expression of CCR4 in TILs significantly increases with the aggression of lung adenocarcinoma and lymph node metastasis， indicating that it may be a predictor of prognosis and therapeutic target in patients with lung adenocarcinoma.

Related Articles | Metrics

Expression of FGFR1， IGF1R in resected squamous cell lung cancer and their clinical significance

ZHOU Yongfang， WANG Meng，YAN An， LI Xiaoli.

Chinese Clinical Oncology. 2014, 19 (12): 1086.

Abstract ( 938 )

PDF（pc） (1602KB) ( 337 )

Save

Objective To investigate the expression of fibroblast growth factor receptor 1（FGFR1）， insulinlike growth factor（IGF1R） in resected squamous cell lung cancer tissue and their clinical significance. Methods The immunohistochemical method was applied to detect the protein expression of FGFR1， IGF1R on tissue sections from 260 squamous cell lung cancer and 40 adjacent normal tissues. Then the relationship between expression of FGFR1， IGF1R and clinicopathological characteristics and prognosis. The overall survival（OS） was estimated using the KaplanMeier method. The factors affecting the prognosis of squamous cell lung cancer were analyzed by Cox multivariate survival analysis. Results The positive expression rates of FGFR1， IGF1R in squamous cell lung cancer tisssues was 32.5％（13／40）and 30.0％（12／40）， higher than 32.5％（13／40）and 30.0％（12／40）of adjacent normal tissues with significant differences（P＜0.05）. FGFR1 expression was related with smoking and lymph node metastasis， and the IGF1R expression was only related with lymph node metastasis（P＜0.05）. The median OS of patients with FGFR1 and IGF1R positive expression was 38.21， 38.48 months， lower than 42.55, 42.51 months of patients with FGFR1 and IGF1R negtive expression（P＜0.05）. Multivariate survival analysis showed that FGFR1， IGF1R expression and lymph node metastasis may act as independent prognostic factors for squamous cell lung cancer. Conclusion Expression of FGFR1 and IGF1R may be involved in the occurrence and development of squamous cell lung cancer.They may serve as markers for predicting the prognosis of patients with squamous cell lung cancer.

Related Articles | Metrics

A meta-analysis of association between CTLA-4+49A／G polymorphism and breast cancer susceptibility

ZHU Yan，GUAN Xiaoxiang，HUA Haiqing，WANG Zexing，YANG Liuqing，CHEN Yingxia，QIN Shukui.

Chinese Clinical Oncology. 2014, 19 (12): 1091.

Abstract ( 989 )

PDF（pc） (2706KB) ( 387 )

Save

Objective To explore the correlation between polymorphism of cytotoxic T lymphocyte antigen-4（CTLA-4）+49A／G and susceptibility to breast cancer. Methods All eligible case-control studies published up to June 2014 were searched out from PubMed， MEDLINE， Web of Science， EMBASE， CNKI and WanFang databases. Two reviewers independently identified the literature，extracted data and assessed the quality of included studies according to inclusion and exclusion criteria. Meta-analysis was performed using RevMan51 software to analyze. Results A total of 5 studies comprising 3237 patients and 3242 controls were finally included. The included studies showed good homogeneity in the four genetic models of AA vs.GG，AG vs.GG，AG／AA vs.GG，A vs.G. There was significant association between CTLA-4+49A／G polymorphism and breast cancer susceptibility（AA vs.GG：OR=1.49， 95％CI：1.10-2.00； AG vs. GG：OR=1.23， 95％CI：1.10-1.37；AG／AAvs.GG：OR=1.27， 95％CI：1.14-1.40；A vs.G：OR=1.19， 95％CI：1.11-1.29）. Conclusion There is significant association between polymorphism of CTLA-4+49A／G and susceptibility to breast cancer.

Related Articles | Metrics

The relationship between C-reactive protein kinetics and efficacy， prognosis of patients with advanced pancreatic cancer

YANG Jiacheng， CAI Xun， SONG Weifeng， WANG Liwei.

Chinese Clinical Oncology. 2014, 19 (12): 1097.

Abstract ( 965 )

PDF（pc） (1110KB) ( 351 )

Save

Objective To investigate the relationship between C-reactive protein（CRP） kinetics and efficacy of the first-line chemotherapy and prognosis， as to analyze whether CRP can be one of the biological markers indicating the clinical prognosis of advanced pancreatic cancer. Methods Sixty-one patients with advanced pancreatic cancer in dignosis and treatment center of pancreatic cancer affiliated to Shanghai Jiaotong university from December 2008 to December 2013 were enrolled in this study. The 61 cases were assigned into four groups according to baseline CRP and CRP kinetics： group A1， patients whose baseline CRP≥5mg／L and never normalized（CRP＜5mg／L） during treatment； group A2， patients whose baseline CRP≥5mg／L and normalized at least one time during treatment； group B1， patients whose baseline CRP＜5mg／L and elevated（CRP≥5mg／L） at least one time during treatment and group B2， patients whose baseline CRP＜5mg／L and never elevated during treatment. The RECIST 1.1 criteria were used to evaluate the curative effect of overall and different CRP group. The Survival data were followed up and analyzed among different groups. The COX proportional hazard regression model was employed to analyze the independent prognostic factors of first-line chemotherapy for advanced pancreatic cancer. Results All patients were evaluable for efficacy. The disease control rate（DCR） was 50.82％ including PR 6 cases， SD 25 cases and PD 4 cases. Until December 31， 2013， 54 cases died and 7 cases survived with medium overall survival（OS） of 7.2 months and medium progressionfree survival（PFS） of 3.03 months. The DCR， medium OS and PFS of A1， A2， B1 and B2 groups were 35.0％， 54.6％， 41.2％ and 84.6％， 4.97， 8.87， 7.20 and 10.47 months， and 1.97， 3.83， 3.20， 6.90 months all with significant difference（P＜0.05）. The independent prognostic factors in patients with advanced pancreatic cancer includes baseline CRP， the dynamic changes of CRP， albumin and CA19-9 levels. Conclusion CRP is one of the biological markers indicating the clinical prognosis of advanced pancreatic cancer. Baseline CRP and CRP kinetics during first-line chemotherapy are independent factors for prognosis of advanced pancreatic cancer.

Related Articles | Metrics

Expression and clinical significance of interferoninduced transmembrane protein 1 in colorectal cancer

DU Nan， ZHU Liqin， SUN Jingyue， HE Jingdong.

Chinese Clinical Oncology. 2014, 19 (12): 1103.

Abstract ( 957 )

PDF（pc） (1528KB) ( 356 )

Save

Objective To examine the expression level of interferon-induced transmembrane protein1（IFITM1） and assess its clinical significance in colorectal cancer. Methods Tissue microarrays were constructed from 144 paraffinembedded tissue blocks containing colorectal cancer with corresponding normal epithelium， and the expression of IFITM1 was tested by immunohistochemistry. The correlations between IFITM1 expression， the clinicopathological factors and overall survival rate were evaluated.
Results Immunohistochemistry demonstrated that strong （7.7％）， moderate （36.9％） and weak （55.4％） expression rate of IFITM1 in colonic cancer tissue were higher than those of adjacent noncancerous tissue（7.7％，36.9％ and 55.4％），with significant difference（P=0.044）. The strong （1.3％）， moderate （39.2％） and weak （59.5％） expression rate of IFITM1 in rectal adenocarcinoma showed no statistic significance compared with （5.1％， 36.9％ and 58.2％）， with no difference （P=0.569）.The expression of IFITM1 was significantly correlated with histological differentiation （P=0.031）. However， the gender， age， tumor location， depth of invasion， lymph node metastasis， and TNM stage had no significant correlation with IFITM1 expression. OS of colorectal cancer patients with high, moderate, low expression of IFITM1 were 34.3, 45.7 and 46.7 months（P=0.700）. Moreover， Kaplan-Meier survival analysis demonstrated that patients with higher IFITM1 expression had worse overall survival outcomes than those with lower levels of IFITM1 expression in rectal cancer （P=0.037）. Mean survival of rectal cancer patients with IFITM1 high expression， moderate expression and low expression was 15.0， 42.7 and 50.1 months respectively. IFITM1 expression was not a significant negative prognostic factor for survival by univariate or multivariate analyses. Conclusion The results suggest that the expression of IFITM1 is associated with poor prognosis in rectal adenocarcinoma. IFITM1 may be a biomarker to predict prognosis in patients with rectal adenocarinoma.

Related Articles | Metrics

Clinic observation of methadone hydrochloride tablets as therapy for 310 patients with severe or refractory cancer pain

HUANG Cheng， CHEN Yigui， ZHANG Jing， XIE Fangwei， KE Mingyao， CHEN Qun， LV Xiaojun，CHEN Yide，CHEN Zhangshu， WANG Xin， ZHANG Jiangling， ZHAN Ying， PANG Hongxia，LAN Zuojun， LIN Xiaoyan， XU Shen，YIN Xiaojian.

Chinese Clinical Oncology. 2014, 19 (12): 1107.

Abstract ( 1162 )

PDF（pc） (892KB) ( 355 )

Save

Objective To evaluate the toxicity and efficacy of methadone hydrochloride tablets as therapy for patients with severe or refractory cancer pain， and the equivalent dose of morphine tablets （dose conversion ratio）， and its safety. Methods Three hundred and ten advanced cancer patients with severe or refractory cancer pain were consecutively enrolled in this study. The patients used morphine sustained-release tablets for the titration， when their pain intensity NRS≤3 then replace methadone hydrochloride tablets for pain treatment. Results Three hundred and five patients with severe or refractory cancer pain who accept methadone hydrochloride tablets treatment for 2 weeks， pain treatment efficient（response rate，RR） was 88.85％. The RR of bone metastases pain， neuropathy pain and refractory cancer pain were 89.89％， 86.08％， 84.62％ respectively. An average daydose of methadone hydrochloride tablets was 24.56±23.69 mg， 94.43％ of patients within 2 times to take medicine in the 305 patients by the second weekend. One hundred and seventytwo patients with successful dose conversion steady state using morphine sustainedrelease tablets dose was 52.08±40.77mg per day， into the second weekend methadone hydrochloride tablets using dose averaged 18.36 ±10.60mg per day， conversion rate was about 3:1. The incidence of adverse events associated with drugs under 1％ of uroschesis，fatigue， illusion， frequent urination， itching， etc.， under 3％ of the incidence of drowsiness，nausea， vomiting and cold sweat， dizziness rate was 8.06％，constipation rate was 18.06％. There was no case of serious adverse events correlative with Methadone Hydrochloride Tablets， laboratory examination found no effect on liver and kidney function and no electrocardiogram （ECG） change. Conclusion Methadone hydrochloride tablets has definite analgesic effect for chronic cancerous pain， dosage is significantly lower than that of morphine. The transformation rate is slightly higher than the NCCN guidelines recommend. The clinical manifestations of the adverse reactions and the incidence are similar to morphin.

Related Articles | Metrics

Clinical observation of recombinant human endostatin durative transfusion combined with window period chemotherapy in advanced non-small cell lung cancer

ZHOU Qing， HU Jingwen， YIN Rong， CHEN Lingxiang， XU Lin， CHEN Jia.

Chinese Clinical Oncology. 2014, 19 (12): 1113.

Abstract ( 1309 )

PDF（pc） (1197KB) ( 699 )

Save

Objective To investigate the safety and efficacy recombinant human endostatin（endostar） durative transfusion combined with window period chemotherapy in advanced non-small cell lung cancer（NSCLC）. Methods From February 2012 to December 2013， 34 cases of ⅢB-Ⅳ NSCLC patients were treated with endostar（15mg／m2） durative transfusion combined with window period chemotherapy. Endostar was durative transfused every 24 hours for 7 days， and in the fourth day of the window period patients were received combined chemotherapy based on platinum， 21 days was a cycle. All patients were received 2-6 cycles； efficacy was evaluated every 2 cycles， and side effects were recorded every 1 cycle. Results Every patient was received at least 2 cycles， got 1 CR， 14 PR， 8 SD and 11 PD. The response rate（RR） of 34 patients was 44.1％， and non-squamous carcinoma was 38. 9％， squamous carcinoma was 50.0％. Fistline treatment of patients showed higher RR（53.9％）. Major toxicities related with endostar were sinus tachycardia in1 case， and 1 case of hypertension. No serious side effects such as bleeding were observed. Conclusion Endostar（15mg／m2） durative transfusion combined with window period chemotherapy for NSCLC was safety and efficacy， and a large prospective randomized controlled clinical study is worth to carry out in future.

Related Articles | Metrics

Clinical observation of erlotinib combined with whole brain radiotherapy for lung adenocarcinoma with brain metastases

GU Hongfang， XU Chunming，WANG Xiangqian， CAI Jing， XIA Xiaochun，YANG Baixia， ZHU Qiwei.

Chinese Clinical Oncology. 2014, 19 (12): 1118.

Abstract ( 996 )

PDF（pc） (924KB) ( 328 )

Save

Objective To investigate the efficacy and side effects of erlotinib plus whole brain radiotherapy（WBRT） in the treatment of lung cancer with brain metastases. Methods Forty-two cases of lung cancer with brain metastases patients from January 2011 to June 2012 in our hospital were randomly divided into treatment group（n=22）and control group（n=20）. 22 patients in treatment group were treated with erlotinib 150mg orally， once per day， combined with WBRT with total dose of 30-36Gy， 3Gy per fraction， five times per week. If the number of brain metastatic lesions were 1-2， shrinkage wild of brain metastases should need extral 16-20Gy／8-10 times after WBRT. Twenty patients in control group were received chemotherapy for 2 cycles（21days was a cycle），and then treated with WBRT， with the same dose and method to treatment group. Patients with ECOG scored 0-1 points were treated by AP or DP solutions. Patients with ECOG scored 2 points were treated with pemetrexed chemotherapy. The curative effects， the survival rate and adverse reaction of two groups were observed and evaluated. Results A total of 42 patients could be evaluated. The RR of brain metastases in treatment group and control group was 86.4％ and 70.0％， respectively（P＞0.05）. The RR of lung primary tumor in treatment group and control group was 40.9％ and 35.0％， respectively（P＞0.05）. The median progress free survival was 8.5 months in treatment group and 4.5 months in the control group（P＞005）. The median survival time was 14.0 months in the treatment group and 9.8 months in the control group（P＞0.05）. 1-year survival rate of two groups were 59.1％ and 450％， and 2-year survival rates were 27.3％ and 15.0％， respectively. They were no statistically significant difference（P＞0.05）. The main adverse reactions in treatment group were only rash and diarrhea， mostly gradeⅠ-Ⅱ， which could be tolerated. The obvious bone marrow suppression and gastrointestinal side effects had no occurrence. In the control group， the adverse reactions were mainly bone marrow suppression， gastrointestinal side effects such as nausea vomiting， which could be relieved by symptomatic treatment. Conclusion Erlotinib combined with WBRT in the treatment of lung cancer with brain metastases can prolong the survival time and were well tolerated for patients.

Related Articles | Metrics

CT-guided percutaneous radiofrequency ablation for specificlocation hepatic carcinoma

GUO Jici，HUANG Dabei，LI Xiaoqun，PENG Guowen，ZHANG Gaoshang，WEN Zixiang，LIU Huilai.

Chinese Clinical Oncology. 2014, 19 (12): 1123.

Abstract ( 1012 )

PDF（pc） (1413KB) ( 364 )

Save

Objective To investigate the efficacy and safety of CT-guided percutaneous radiofrequency ablation（RFA） in the treatment of specificlocation hepatic carcinoma. Methods From May 2008 to April 2012， 47 patients with 63 maglignant hepatic lesions which are less than 3cm and close to the large vessels or important extrahepatic organs were treated by CTguided percutaneous radiofrequency ablation. All patients were followed up by clinical and enhancements CT scan respectively in the first month， third month， sixth month， ninth month and twelveth month after RFA. The categorical data such as complete necrosis rate， local tumor progression rate， tumor intrahepatic recurrence rate and survival rate were analyzed. Results All patients were received CTguided percutaneous radiofrequency ablation successfully. The complete necrosis rate of specificlocation hepatic carcinoma was 88.89％（56／63） in one month after RFA. The local tumor progression rate was 4.77％（3／63）， 3.17％（2／63）， 3.17％（2／63） and 1.59％（1／63） respectively in the third， sixth， ninth and twelfth month after RFA. The tumor intrahepatic recurrence rate was 15.87％（10／63）， 4.76％（3／63）， 12.70％（8／63）and 3.17％（2／63） in the third， sixth， ninth and twelfth month after RFA. During the follow-up period， the 1-， 3-， 5-year survival rates of 47 patients were 82.98％（39／47）， 63.83％（30／47） and 36.17％（17／47） after RFA. No severe complications occurred. There were 6 cases complicated with hepatic subcapsular hematoma， 10 cases complicated with postoperative fever which were relieved by symptomatic treatment. Conclusion CT-guided percutaneous radiofrequency ablation for specificlocation hepatic carcinoma was safe and effective.

Related Articles | Metrics

Argon-helium cryoablation therapy for solitary pulmonary nodule

LIU Li， SHAO Tianpeng， CAO Jianmin， LU Guangming， XU Jian.

Chinese Clinical Oncology. 2014, 19 (12): 1128.

Abstract ( 1053 )

PDF（pc） (1056KB) ( 353 )

Save

Objective To evaluate the value and safety of argon-helium cryoablation in the treatment of solitary pulmonary nodule（SPN）. Methods The clinical data of 34 patients who diagnosed as SPNs by CT from January 2006 to May 2014 were reviewed. All the patients underwent biopsy and argonhelium cryoablation. CT features was applied to evaluate the clinical efficacy of argon-helium cryoablation treatment. Results All patients were diagnosed as malignant lesions by CT imaging. There were 34 patients diagnosed as 25 lung adenocarcinoma， 6 lung squamous cancer and 3 colon metastatic cancer by biopsy. The 34 patients were successfully completed argonhelium cryoablation treatment. Intraoperative CT view demonstrated that the focal area of ice hockey completely covered 30 cases， and the other 4 cases of ice hockey covering 90％ lesions. There were not intraoperative and postoperative pleural effusion， subcutaneous emphysema and pulmonary infection. Three months after operation， the CT scan displayed that there were CR in 18 patients， PR in 12， NC in 4 patients， and the effective rate was 88.2％. Six months after operation， the CT scan displayed that there were CR in 18 patients， PR in 12 patients， NC in 2， PD in 2 patients， and the effective rate was 88.2％. Twelve months after operation， the CT scan displayed that there were CR in 18 patients， PR in 10 patients， NC in 1 patient， PD in 5 patients， and the total effective rate was 82.3％. There were pneumothorax without symptoms in 2 cases， a small number of haemoptysis in 8 cases， mild chest pain in 5 cases， mild chest tightness in 10 cases， and fever in 6 cases after the operation. The 2-， 5-year survival rate was 61.7％ and 38.2％. Conclusion Argon-helium cryoablation is safe and effective treatment for SPN that can't resected by surgery.

Related Articles | Metrics

Clinical observation of groin incision healing after inguinal lymphadenectomy of vulvar cancer

WU Qiang， LI Rong， ZHAO Yibing， DAI Zhiqin， SHAO Henghua， SUN Zhihua， QU Junwei， SHEN Yang，FANG Yichen， LI Juan.

Chinese Clinical Oncology. 2014, 19 (12): 1132.

Abstract ( 940 )

Save

Objective To explore the feasibility of malignant inguinal lymphadenectomy improving surgical incision under the suture and laparoscopic inguinal lymph node dissection of the vulva cancer. Methods A retrospective analysis on groin incision healing time， healing rate of stageⅠand delayed healing rate were made among the following three groups： improved suture skill group， traditional suture skill group and endoscopic inguinal lymphadenectomy group. Results The average healing time of a groin incision in traditional group of 16 patients was （28.0±19.2）d， including 6 cases with healing at stageⅠ； and the average healing time of 9 patients in improved group was （14.2±6.2）d and 8 cases healed at stageⅠ. The healing rate at stageⅠin laparoscopic group of 16 cases was 93.8％（1 patient with diabetes delayed healing）. The average healing time in traditional group was significantly longer than those in the other two groups（P＜0.05）.The delay healing rate of traditional group was 62.5％， significantly higher than 11.1％， 6.2％ of improved group and laparoscopic group（P＜0.05）， but there was no significant difference between improved group and laparoscopic group in the delay healing rate（P＞0.05）. Conclusion The improved suture methods and laparoscopic inguinal lymphadenectomy surgical methods are better than the traditional suture method on skin incision healing of the groin area，which is worth of popularizing and applying.

Related Articles | Metrics

Analysis of clinical manifestations and treatment of pulmonary Langerhans cell histiocytosis： A 17 cases report

LU Shifeng， FANG Yongjun， RUI Yaoyao， HE Lulu， ZHOU Li， HUANG Jie， WU Peng， LIN Rufeng， WANG Yongren， LU Qin.

Chinese Clinical Oncology. 2014, 19 (12): 1135.

Abstract ( 977 )

Save

Objective To study the characteristic clinical manifestations， CT manifestations， diagnosis and treatment characteristics， and analyze its relationships with prognosis of the children with pulmonary Langerhans cell histiocytosis（PLCH）. Methods In a retrospective study， the clinical features and imaging data of 17 children with PLCH were analyzed as well as the efficacy and prognosis after type Ⅲ chemotherapy of 6week induction phase and 52-week maintenance phase. Results All children suffered onset pulmonary diffuse change with multiple organ damage and in the process of disease development； most of the chest computed tomography（CT） showed characteristic changes. All the 17 children were received type Ⅲ chemotherapy， and 8 cases got complete remission with good prognosis， 4 cases relapsed after chemotherapy including 1 case with good prognosis and 3 cases of death， 3 cases abandoned treatment due to progression during chemotherapy. In addition， 1 case with progression received reinduction chemotherapy and survived with the present continuous chemotherapy. One case of maintenance chemotherapy treatment was followed-up. Conclusion Children with PLCH were infants and young children with multiple organ damage. Early intenstive chemotherapy can improve the prognosis， but some cases of lung progress are apparent.

Related Articles | Metrics

Progression of hypoxiainducible factor-1 alpha in photodynamic therapy of tumor

JIANG Cailing， BAI Yuxian， LI Yanjing， XIE Rui.

Chinese Clinical Oncology. 2014, 19 (12): 1138.

Abstract ( 1027 )

PDF（pc） (948KB) ( 348 )

Save

Malignant tumors have become the leading cause of human death. Conventional anticancer treatment modalities， such as surgery， radiation and chemotherapy， are often deleterious to the patient due to the numerous associated side effects. Photodynamic therapy（PDT） as a new approach available to cancer therapy， with its unique targeting and nondrug resistance， caused more and more attention of scholars. Previous studies have shown that PDT destructed tumor by a variety of mechanisms. In addition to the known mechanism of necrosis and apoptosis， inflammatory reaction after PDT can also indirectly help the removal of tumor cells. Hypoxiainducible factor-1alpha（HIF-1α） is a nucleoprotein with transcriptional activity， possessing a wide spectrum of target genes（such as hypoxia adaptation， inflammation development and tumor growth）， which include vascular endothelial growth factor（VEGF）， one of the most important genes in promoting vascularization. In this review， we discuss the role of HIF-1α in the PDT of tumor cells.

Related Articles | Metrics

The role of androgen receptor in proliferation and relative molecules expression of breast cancer cell

ZHU Aiyu，GUAN Xiaoxiang.

Chinese Clinical Oncology. 2014, 19 (12): 1143.

Abstract ( 972 )

Save

Breast cancer is known as a hormoneresponsive cancer. Apart from estrogen，androgen also plays a critical role in the occurrence and development of breast cancer. The binding of androgen to androgen receptor（AR）leads to the activation of AR， which interacts with molecules in the nuclear， resulting in up-regulation or down-regulation of target proteins. AR is associated with the expression of ERs， aromatase， human epidermal growth factor receptor-2（HER-2）， progesterone receptor（PR） and Ecadherin. The resistant mechanisms of aromatase inhibitions（AIs） and selective estrogen receptor modulators（SERMs） Tamoxifen are also relevant with AR. Further investigation of AR signaling makes it possible to be an effective therapeutic target for breast cancer.

Related Articles | Metrics

Progression of miRNA in endocrine therapy-resistance breast cancer

CHEN Jingyu， ZHANG Qingyuan.

Chinese Clinical Oncology. 2014, 19 (12): 1147.

Abstract ( 954 )

Save

Endocrine therapy is most effective adjuvant treatment for estrogen receptor（ER） positive breast cancer， significantly improving disease free survival and overall survival. However， endocrine treatment failure due to drug resistance leads to poor prognosis in some patients. Recently， microRNA（miRNA） is becoming a hotspot in the field of cancer research. More and more studies demonstrated that the expression and regulation of various miRNA was one of the key factors of drug resistance mechanisms of breast cancer. MiRNA stimulated epithelialmesenchymal transition and cancer stem cells formation by modulating drug efflux transporters， antiapoptotic protein and multidrug resistance signal transduction networks. Recent studies found that miRNA could control endocrine resistance mainly by regulating ERα expression， tyrosine kinase receptor signal transduction， survival signaling and apoptosis pathway. Many studies showed that miRNA might be prognostic factor for hormone receptor positive breast cancer and predict factor for assessing the efficacy of endocrine therapy. As a new molecular marker， it is possible that miRNA can provide a new target to overcome endocrine therapy resistance so as to further improve endocrine therapy efficient of breast cancer.

Related Articles | Metrics

标准刊号：	ISSN 1009-0460
	CN 32-1577/R